Post-earnings recap
Reported
Tue, Nov 6, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
Eli Lilly's earnings report showed a slight miss on EPS, which contributed to a 3.85% decline in stock price. Investors may be concerned about the lack of revenue details and forward guidance, leading to uncertainty in the stock's near-term performance. The company's focus on R&D suggests a long-term strategy, but immediate reactions reflect caution among investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.39 | N/A | -2.03% |
Management remains focused on innovation and future product pipelines. They acknowledged the current market pressures but are optimistic about future opportunities.
Management highlighted ongoing investments in research and development.
They expressed confidence in long-term growth despite current challenges.
Est. EPS
—
Est. Rev
—
Impl. Move
—